Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 7,924 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Christine Fox sold 7,924 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $250,953.08. Following the sale, the executive vice president directly owned 84,905 shares of the company’s stock, valued at $2,688,941.35. This represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Teva Pharmaceutical Industries Trading Up 1.3%

Shares of TEVA stock traded up $0.39 on Monday, reaching $31.44. 11,093,245 shares of the stock were exchanged, compared to its average volume of 9,695,220. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $36.15 billion, a P/E ratio of 26.20, a price-to-earnings-growth ratio of 10.39 and a beta of 0.72. The firm has a 50 day moving average of $33.01 and a two-hundred day moving average of $26.32. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter last year, the firm earned $0.71 earnings per share. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently bought and sold shares of TEVA. Aster Capital Management DIFC Ltd acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Allworth Financial LP lifted its position in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust boosted its stake in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the period. Finally, Advisors Asset Management Inc. acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $41,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. Piper Sandler reiterated an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Scotiabank increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.